Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a lethal brain tumour in adults and children. However, DNA copy number and gene expression signatures indicate differences between adult and paediatric cases. To explore the genetic events underlying this distinction, we sequenced the exomes of 48 paediatric GBM samples. Somatic mutations in the H3.3-ATRX-DAXX chromatin remodelling pathway were identified in 44% of tumours (21/48). Recurrent mutations in H3F3A, which encodes the replication-independent histone 3 variant H3.3, were observed in 31% of tumours, and led to amino acid substitutions at two critical positions within the histone tail (K27M, G34R/G34V) involved in key regulatory post-translational modifications. Mutations in ATRX (α-thalassaemia/mental retardation syndrome X-linked) and DAXX (death-domain associated protein), encoding two subunits of a chromatin remodelling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres, were identified in 31% of samples overall, and in 100% of tumours harbouring a G34R or G34V H3.3 mutation. Somatic TP53 mutations were identified in 54% of all cases, and in 86% of samples with H3F3A and/or ATRX mutations. Screening of a large cohort of gliomas of various grades and histologies (n = 784) showed H3F3A mutations to be specific to GBM and highly prevalent in children and young adults. Furthermore, the presence of H3F3A/ATRX-DAXX/TP53 mutations was strongly associated with alternative lengthening of telomeres and specific gene expression profiles. This is, to our knowledge, the first report to highlight recurrent mutations in a regulatory histone in humans, and our data suggest that defects of the chromatin architecture underlie paediatric and young adult GBM pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone H3 lysine27-to-methionine (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [3]
In the citing paper
“Indeed, the K27M mutation has been observed to occur in genes encoding all forms of histone H3 (H3.1, H3.2, and H3.3) in human glioma (1,10,24).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [1]
In the citing paper
“ALT is associated with mutations in the chromatin remodeller α-thalassaemia/mental retardation syndrome X-linked (AT R X ) both in vitro and in several human cancers, including glioblastomas162–165.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [163]
In the citing paper
“The H3.3G34R/V mutated tumours are found almost exclusively in the cerebral hemispheres 101,102 , whereas H3.1K27M tumours are restricted to an area of the brainstem called the pons and H3.3K27M tumours can also be found along the midline of the brain 106 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [106]
In the citing paper
“A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors, and results in a lysine-to-methionine substitution (H3K27M)2,3.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [2]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Cited by
Items 201–300 of 1,001
Histone variants: key players of chromatin
Biterge, B., & Schneider, R. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1862-4 · Cited by 182
“3 at glycine 34 to valine or arginine and lysine 27 (which can be methylated or acetylated) to methionine have been found in 31 % of pediatric glioma tumors (Schwartzentruber et al. 2012).”
BackgroundMolecular architecture of polycomb repressive complexes
Chittock, E. C., Latwiel, S., Miller, T. C. R., & Müller, C. W. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160173 · Cited by 187
ATRX and DAXX: Mechanisms and Mutations
Dyer, M. A., Qadeer, Z. A., Valle-Garcia, D., & Bernstein, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026567 · Cited by 194
Chromatin accessibility profiling methods
Minnoye, L., Marinov, G. K., Krausgruber, T., Pan, L., Marand, A. P., Secchia, S., Greenleaf, W. J., Furlong, E. E. M., Zhao, K., Schmitz, R. J., et al. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-020-00008-9 · Cited by 206
Role of the cGAS–STING pathway in cancer development and oncotherapeutic approaches
Khoo, L. T., & Chen, L. (2018) · The EMBO Reports · doi:10.15252/embr.201846935 · Cited by 204
Min, J., Wright, W. E., & Shay, J. W. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00226-17 · Cited by 195
Chung, C., Sweha, S. R., Pratt, D., Tamrazi, B., Panwalkar, P., Banda, A., Bayliss, J., Hawes, D., Yang, F., Lee, H.-J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.008 · Cited by 203
“Importantly, analysis of publicly available data sets (TCGA) in a glioma cohort (n=720) demonstrated that mIDH1/2 (n=463) and H3K27M (n=257) were mutually exclusive and occurred in divergent age groups (Figure 7D) (Schwartzentruber et al., 2012; Sturm et al., 2012).”
Molecular mechanisms of activity and derepression of alternative lengthening of telomeres
Pickett, H. A., & Reddel, R. R. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3106 · Cited by 203
Molecular neuro-oncology in clinical practice: a new horizon
Weller, M., Pfister, S. M., Wick, W., Hegi, M. E., Reifenberger, G., & Stupp, R. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70168-2 · Cited by 189
“3 gene (H3F3A).(32,33) These mutations cluster at two critical amino acid residues, namely K27 and G34.”
BackgroundSelf-citationDNA repair mechanisms and their clinical impact in glioblastoma
Erasimus, H., Gobin, M., Niclou, S., & Van Dyck, E. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.05.005 · Cited by 188
Kleinman, C. L., Gerges, N., Papillon-Cavanagh, S., Sin-Chan, P., Pramatarova, A., Quang, D.-A. K., Adoue, V., Busche, S., Caron, M., Djambazian, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2849 · Cited by 198
Self-citationH3F3A K27M mutations in thalamic gliomas from young adult patients
Aihara, K., Mukasa, A., Gotoh, K., Saito, K., Nagae, G., Tsuji, S., Tatsuno, K., Yamamoto, S., Takayanagi, S., Narita, Y., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not144 · Cited by 199
“For DIPGs, a small number of low-grade astrocytomas were reported to have the H3F3A K27M mutation,(8) but in general the H3F3A K27M mutation seemed to be specific to high-grade gliomas.(5,7,18) H3F3A encodes H3.”
BackgroundNon-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma
Lin, G. L., Nagaraja, S., Filbin, M. G., Suvà, M. L., Vogel, H., & Monje, M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0553-x · Cited by 196
“A highly recurrent mutation in genes encoding histone-3 (H3K27M) is found in ~ 80% of all DIPG and also the majority of thalamic and spinal cord gliomas of childhood [2, 9, 11, 22, 44, 45, 48, 50, 53, 54]; these H3K27M mutant gliomas were recently reclassified as “diffuse midline gliomas, H3K27M mutant subtype” [23].”
BackgroundThe Epigenetic Hallmarks of Cancer
Esteller, M., Dawson, M. A., Kadoch, C., Rassool, F. V., Jones, P. A., & Baylin, S. B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0296 · Cited by 160
Cleven, A. H. G., Höcker, S., Briaire-de Bruijn, I., Szuhai, K., Cleton-Jansen, A.-M., & Bovée, J. V. M. G. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000512 · Cited by 200
“Female 34 (56) 2 (17) Male 26 (44) 10 (83) Tumor location (n [%]) Femur 23 (38) 2 (17) Tibia 10 (17) 1 (8) Fibula 6 (10) 0 (0)”
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach
Presta, M., Chiodelli, P., Giacomini, A., Rusnati, M., & Ronca, R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.013 · Cited by 198
Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling
Herz, H.-M., Morgan, M., Gao, X., Jackson, J., Rickels, R., Swanson, S. K., Florens, L., Washburn, M. P., Eissenberg, J. C., & Shilatifard, A. (2014) · Science · doi:10.1126/science.1255104 · Cited by 199
“3K27M) occur in a subtype of aggressive pediatric brain cancers [3, 4], and act in a dominant manner to deplete H3K27 methylation by inhibiting PRC2 methyltransferase activity [5, 6].”
BackgroundHistone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis
Chen, C. C. L., Deshmukh, S., Jessa, S., Hadjadj, D., Lisi, V., Andrade, A. F., Faury, D., Jawhar, W., Dali, R., Suzuki, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.012 · Cited by 188
“In addition to the known genetic alterations in TP53 and ATRX (95% and 84% respectively), we observed a specific, previously unappreciated high frequency of mutations in PDGFRA in G34R/V HGGs (46/95), which also showed a high level of Cell.”
BackgroundInfluentialSelf-citationGuo, Y., Zhao, S., & Wang, G. G. (2021) · Trends in Genetics · doi:10.1016/j.tig.2020.12.006 · Cited by 180
Voon, H. P. J., Hughes, J. R., Rode, C., De La Rosa-Velázquez, I. A., Jenuwein, T., Feil, R., Higgs, D. R., & Gibbons, R. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.036 · Cited by 193
“3 pathway have been linked to certain cancers and an alternative lengthening of telomeres (ALT) phenotype (Heaphy et al., 2011; Jiao et al., 2011; Lovejoy et al., 2012; Schwartzentruber et al., 2012), demonstrating the importance of this pathway in maintaining chromatin integrity and, with it, genomic stability.”
BackgroundHoffman, L. M., DeWire, M., Ryall, S., Buczkowicz, P., Leach, J., Miles, L., Ramani, A., Brudno, M., Kumar, S. S., Drissi, R., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0269-0 · Cited by 199
“As expected, H3G34R/V mutations, predominantly reported in hemispheric pediatric HGGs [25], were also not found.”
BackgroundInfluentialSmall is Smarter: Nano MRI Contrast Agents – Advantages and Recent Achievements
Gao, Z., Ma, T., Zhao, E., Docter, D., Yang, W., Stauber, R. H., & Gao, M. (2016) · Small · doi:10.1002/smll.201502309 · Cited by 195
Bayliss, J., Mukherjee, P., Lu, C., Jain, S. U., Chung, C., Martinez, D., Sabari, B., Margol, A. S., Panwalkar, P., Parolia, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aah6904 · Cited by 191
“In contrast, H3K27me3 is retained in ST gliomas [which bear H3G34R/V (G34) mutations] and in ST ependymomas (with C11orf95-RELA fusions) (5, 17, 18).”
BackgroundPanditharatna, E., Kilburn, L. B., Aboian, M. S., Kambhampati, M., Gordish-Dressman, H., Magge, S. N., Gupta, N., Myseros, J. S., Hwang, E. I., Kline, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1345 · Cited by 194
“Collection of postmortem specimens led to the identification of oncohistones as driver mutations as well as other partner mutations, and newer clinical trials are building upon this knowledge to identify rational, biologically targeted treatment approaches (4, 5, 25).”
BackgroundAnastas, J. N., Zee, B. M., Kalin, J. H., Kim, M., Guo, R., Alexandrescu, S., Blanco, M. A., Giera, S., Gillespie, S. M., Das, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.005 · Cited by 184
“Given that the H3K27M substitution observed in DIPG is found in the histone tail region that is subject to extensive covalent modification, it has been hypothesized that these mutations might disrupt the pattern of chromatin modifications leading to epigenetic mis-regulation (Fontebasso et al., 2013; Jones and Baker,…”
BackgroundInfluentialWiestler, B., Capper, D., Sill, M., Jones, D. T. W., Hovestadt, V., Sturm, D., Koelsche, C., Bertoni, A., Schweizer, L., Korshunov, A., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1315-x · Cited by 194
“Mutually exclusive mutations affecting telomerase reverse transcriptase (TERT) and alpha-thalassemia/mental retardation syndrome X-linked (ATRX) have been detected in malignant gliomas [11, 21].”
Self-citationWhole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
Fishbein, L., Khare, S., Wubbenhorst, B., DeSloover, D., D’Andrea, K., Merrill, S., Cho, N. W., Greenberg, R. A., Else, T., Montone, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms7140 · Cited by 185
Vinci, M., Burford, A., Molinari, V., Kessler, K., Popov, S., Clarke, M., Taylor, K. R., Pemberton, H. N., Lord, C. J., Gutteridge, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0086-7 · Cited by 179
Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks
Zhang, J.-M., & Zou, L. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00391-6 · Cited by 181
Hennika, T., Hu, G., Olaciregui, N. G., Barton, K. L., Ehteda, A., Chitranjan, A., Chang, C., Gifford, A. J., Tsoli, M., Ziegler, D. S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169485 · Cited by 191
Pediatric High Grade Glioma: a Review and Update on Tumor Clinical Characteristics and Biology
Fangusaro, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00105 · Cited by 183
Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation
Aboian, M. S., Solomon, D. A., Felton, E., Mabray, M. C., Villanueva-Meyer, J. E., Mueller, S., & Cha, S. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5076 · Cited by 186
Nagaraja, S., Quezada, M. A., Gillespie, S. M., Arzt, M., Lennon, J. J., Woo, P. J., Hovestadt, V., Kambhampati, M., Filbin, M. G., Suva, M. L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.030 · Cited by 185
“The hallmark of midline pediatric gliomas is a substitution to methionine in histone H3 at lysine 27 (H3K27M), present in 80% of DIPG cases (Khuong-Quang et al., 2012; Schwartzentruber et al., 2012; Wu et al., 2012; Aihara et al., 2014; Gessi et al., 2015; Mackay et al., 2017).”
BackgroundSelf-citationDriver mutations of cancer epigenomes
Roy, D. M., Walsh, L. A., & Chan, T. A. (2014) · Protein & Cell · doi:10.1007/s13238-014-0031-6 · Cited by 186
“Likewise, a groundbreaking study by Sturm and colleagues revealed distinct epigenetic subtypes of GBM, with K27 and G34 mutant tumor samples exhibiting independent gene expression and methylation profiles (Bjerke et al., 2013; Schwartzentruber et al., 2012; Sturm et al., 2012).”
BackgroundInfluentialExome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas
Zhang, L., Chen, L. H., Wan, H., Yang, R., Wang, Z., Feng, J., Yang, S., Jones, S., Wang, S., Zhou, W., et al. (2014) · Nature Genetics · doi:10.1038/ng.2995 · Cited by 187
Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel
Zacher, A., Kaulich, K., Stepanow, S., Wolter, M., Köhrer, K., Felsberg, J., Malzkorn, B., & Reifenberger, G. (2017) · Brain Pathology · doi:10.1111/bpa.12367 · Cited by 181
“In pediatric glioblastomas and diffuse intrinsic pontine gliomas, mutations in the H3 histone family 3A (H3F3A) gene, often associated with ATRX and TP53 mutations, have been identified as frequent alterations (46, 64).”
BackgroundSelf-citationGABAergic neuron-to-glioma synapses in diffuse midline gliomas
Barron, T., Yalçın, B., Su, M., Byun, Y. G., Gavish, A., Shamardani, K., Xu, H., Ni, L., Soni, N., Mehta, V., et al. (2025) · Nature · doi:10.1038/s41586-024-08579-3 · Cited by 161
Reis, G. F., Pekmezci, M., Hansen, H. M., Rice, T., Marshall, R. E., Molinaro, A. M., Phillips, J. J., Vogel, H., Wiencke, J. K., Wrensch, M. R., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000188 · Cited by 184
Glioblastoma cancer stem cell biology: Potential theranostic targets
Sharifzad, F., Ghavami, S., Verdi, J., Mardpour, S., Mollapour Sisakht, M., Azizi, Z., Taghikhani, A., Łos, M. J., Fakharian, E., Ebrahimi, M., et al. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.003 · Cited by 175
de Wilde, R. F., Heaphy, C. M., Maitra, A., Meeker, A. K., Edil, B. H., Wolfgang, C. L., Ellison, T. A., Schulick, R. D., Molenaar, I. Q., Valk, G. D., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.53 · Cited by 181
Wang, Y., Yang, J., Wild, A. T., Wu, W. H., Shah, R., Danussi, C., Riggins, G. J., Kannan, K., Sulman, E. P., Chan, T. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08905-8 · Cited by 184
Metabolic therapy: A new paradigm for managing malignant brain cancer
Seyfried, T. N., Flores, R., Poff, A. M., D’Agostino, D. P., & Mukherjee, P. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.07.015 · Cited by 181
Phosphorylation of histone H3.3 at serine 31 promotes p300 activity and enhancer acetylation
Martire, S., Gogate, A. A., Whitmill, A., Tafessu, A., Nguyen, J., Teng, Y.-C., Tastemel, M., & Banaszynski, L. A. (2019) · Nature Genetics · doi:10.1038/s41588-019-0428-5 · Cited by 175
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
Prabhu, V. V., Morrow, S., Rahman Kawakibi, A., Zhou, L., Ralff, M., Ray, J., Jhaveri, A., Ferrarini, I., Lee, Y., Parker, C., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.09.005 · Cited by 174
“Tumor cells harboring this mutation exhibit a histone hypomethylation profile that causes epigenetic dysregulation of the expression of many genes associated with cancer [104,105].”
BackgroundPan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhauser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 175
“Table 2 Pan-cancer patterns of DNA methylation Tumor type (number of methylation groups) Methylation subgroup Genomic aberrations Methylation pattern* Comments References AML High IDH1/2 or TET2 mutations A Associated with patients presenting with an intermediate-risk karyotype [43,51,107] Co-occurrence of IDH1/2 and…”
BackgroundSelf-citationDe Vitis, M., Berardinelli, F., & Sgura, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020606 · Cited by 182
ATRX represses alternative lengthening of telomeres
Napier, C. E., Huschtscha, L. I., Harvey, A., Bower, K., Noble, J. R., Hendrickson, E. A., & Reddel, R. R. (2015) · Oncotarget · doi:10.18632/oncotarget.3846 · Cited by 181
“More recently, it was found that inactivating mutations in one or other of the genes encoding the ATRX/DAXX chromatin remodeling complex, most commonly ATRX, are very common in ALT-positive tumors and cell lines [6-10].”
BackgroundGreater Than the Sum of Parts: Complexity of the Dynamic Epigenome
Soshnev, A. A., Josefowicz, S. Z., & Allis, C. D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.004 · Cited by 174
Huang, T. Y., Piunti, A., Lulla, R. R., Qi, J., Horbinski, C. M., Tomita, T., James, C. D., Shilatifard, A., & Saratsis, A. M. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0436-6 · Cited by 176
“3 G34V/R) The K27M mutation is observed in up to 80% of diffuse midline gliomas, and G34V/R mutations occurs in up to 30% of hemispheric pediatric gliomas [10, 20, 33, 38].”
BackgroundHistone variants: emerging players in cancer biology
Vardabasso, C., Hasson, D., Ratnakumar, K., Chung, C.-Y., Duarte, L. F., & Bernstein, E. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1343-z · Cited by 165
“Recent insights have shed light on the mechanistic role of histone variants in cancer progression [11–14] and, remarkably, the first histone variant mutations have just been uncovered in cancer [15, 16].”
BackgroundFunctions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway
Yazinski, S. A., & Zou, L. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-121415-121658 · Cited by 175
Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells
Conomos, D., Stutz, M. D., Hills, M., Neumann, A. A., Bryan, T. M., Reddel, R. R., & Pickett, H. A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201207189 · Cited by 165
“For instance, further genetic alterations such as loss of ATRX, which has recently been shown to be widely mutated in ALT tumors and immortalized cell lines (Heaphy et al., 2011; Lovejoy et al., 2012; Schwartzentruber et al., 2012), may be required for complete ALT activation.”
BackgroundAtrx promotes heterochromatin formation at retrotransposons
Sadic, D., Schmidt, K., Groh, S., Kondofersky, I., Ellwart, J., Fuchs, C., Theis, F. J., & Schotta, G. (2015) · EMBO reports · doi:10.15252/embr.201439937 · Cited by 168
“3 deposition pathway is frequently mutated in pancreatic neuroendocrine tumors, glioblastoma, and pediatric neuroendocrine tumors [31 – 35].”
A Recurrent PDGFRB Mutation Causes Familial Infantile Myofibromatosis
Cheung, Y. H., Gayden, T., Campeau, P. M., LeDuc, C. A., Russo, D., Nguyen, V.-H., Guo, J., Qi, M., Guan, Y., Albrecht, S., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.04.026 · Cited by 174
“Reads were aligned against the reference human genome (UCSC Genome Browser hg19) with BWA,(8) variants called and annotated as previously described.(9) Given the rarity of the disease, we eliminated variants with minor allele frequency (MAF) greater than 1% in the 1000 Genomes(10) and NHLBI GO Exome Sequencing Project…”
MethodSelf-citationPediatric low-grade gliomas: next biologically driven steps
Jones, D. T. W., Kieran, M. W., Bouffet, E., Alexandrescu, S., Bandopadhayay, P., Bornhorst, M., Ellison, D., Fangusaro, J., Fisher, M. J., Foreman, N., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox141 · Cited by 167
Self-citationCancer Epigenetics: An Overview
Targa, F. R. (2022) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.11.003 · Cited by 184
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 166
“3/ATRX/DAXX also have several strong links to 2-HG.”
InfluentialExtrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway
Chen, Y.-A., Shen, Y.-L., Hsia, H.-Y., Tiang, Y.-P., Sung, T.-L., & Chen, L.-Y. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3498 · Cited by 160
Surgical resection of malignant gliomas—role in optimizing patient outcome
Eyüpoglu, I. Y., Buchfelder, M., & Savaskan, N. E. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.279 · Cited by 159
Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimics
Presneau, N., Baumhoer, D., Behjati, S., Pillay, N., Tarpey, P., Campbell, P. J., Jundt, G., Hamoudi, R., Wedge, D. C., Loo, P. V., et al. (2015) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.13 · Cited by 163
“G34M in aggressive brain tumours, in which TP53 mutations are also seen [17], the 3 GCT with these alterations followed a typical clinical course and did not harbour TP53 mutations, with 2/3 having at least 5 years follow-up (p.”
Pediatric high-grade glioma: current molecular landscape and therapeutic approaches
Braunstein, S., Raleigh, D., Bindra, R., Mueller, S., & Haas-Kogan, D. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2393-0 · Cited by 160
“3, occur in approximately one-third of pediatric glioblastomas [64, 67, 78].”
BackgroundDubbink, H. J., Atmodimedjo, P. N., Kros, J. M., French, P. J., Sanson, M., Idbaih, A., Wesseling, P., Enting, R., Spliet, W., Tijssen, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov182 · Cited by 163
“10 y), 96% of the tumor samples could be successfully analyzed; and of those, 95% could be identified molecularly as either type I (oligodendroglioma), type II (astrocytoma), or type III (glioblastoma) (n1⁄4 124) or as a childhood glioblastoma (presence of an H3F3A mutation, n1⁄4 2).(40) The survival rates of patients…”
BackgroundMyeloid malignancies: mutations, models and management
Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M.-J., Gelsi-Boyer, V., & Birnbaum, D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-304 · Cited by 139
Rai, T. S., Cole, J. J., Nelson, D. M., Dikovskaya, D., Faller, W. J., Vizioli, M. G., Hewitt, R. N., Anannya, O., McBryan, T., Manoharan, I., et al. (2014) · Genes & Development · doi:10.1101/gad.247528.114 · Cited by 162
“1 (HIST3H1B) in some cancers, in particular in pediatric gliomas (Schwartzentruber et al. 2012; Sturm et al. 2012; Wu et al. 2012; Yuen and Knoepfler 2013).”
Janssens, G. O. R. J., Gandola, L., Bolle, S., Mandeville, H., Albiac, M. R., Beek, K. V., Benghiat, H., Hoeben, B. A. W., Madrid, A. M. L., Kortmann, R., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.007 · Cited by 162
Self-citationHistone variants in pluripotency and disease
Skene, P. J., & Henikoff, S. (2013) · Development · doi:10.1242/dev.091439 · Cited by 151
“3 (K27M and G34R/V) have been found in a large fraction of pediatric glioblastomas, in which mutations in ATRX and DAXX are also frequently found (Schwartzentruber et al., 2012; Wu et al., 2012).”
BackgroundMutant ATRX: uncovering a new therapeutic target for glioma
Haase, S., Garcia-Fabiani, M. B., Carney, S., Altshuler, D., Núñez, F. J., Méndez, F. M., Núñez, F., Lowenstein, P. R., & Castro, M. G. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1487953 · Cited by 158
“[16,88,92,93] which also usually co-occurs with TP53 mutations [16,83], overlaps less frequently with ATRX mutations (22–60%)”
BackgroundInfluentialRevisiting Telomere Shortening in Cancer
Okamoto, K., & Seimiya, H. (2019) · Cells · doi:10.3390/cells8020107 · Cited by 152
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
Jones, D. T. W., Banito, A., Grünewald, T. G. P., Haber, M., Jäger, N., Kool, M., Milde, T., Molenaar, J. J., Nabbi, A., Pugh, T. J., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0169-x · Cited by 161
Self-citationThe Role of Telomere Biology in Cancer
Xu, L., Li, S., & Stohr, B. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164030 · Cited by 160
Mechanisms of Polycomb group protein function in cancer
Parreno, V., Martinez, A., & Cavalli, G. (2022) · Cell Research · doi:10.1038/s41422-021-00606-6 · Cited by 168
Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG
Cordero, F. J., Huang, Z., Grenier, C., He, X., Hu, G., McLendon, R. E., Murphy, S. K., Hashizume, R., & Becher, O. J. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0389 · Cited by 157
RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action
Masliah‐Planchon, J., Garinet, S., & Pasmant, É. (2015) · Oncotarget · doi:10.18632/oncotarget.6476 · Cited by 165
“3, a region that is frequently loss in human GBM [27].”
BackgroundInfluentialHasselblatt, M., Isken, S., Linge, A., Eikmeier, K., Jeibmann, A., Oyen, F., Nagel, I., Richter, J., Bartelheim, K., Kordes, U., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22018 · Cited by 158
Self-citationHübner, J.-M., Müller, T., Papageorgiou, D. N., Mauermann, M., Krijgsveld, J., Russell, R. B., Ellison, D. W., Pfister, S. M., Pajtler, K. W., & Kool, M. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz058 · Cited by 161
Self-citationKim, J. Y., Brosnan‐Cashman, J. A., An, S., Kim, S. J., Song, K. B., Kim, M. S., Kim, M.-J., Hwang, D. W., Meeker, A. K., Yu, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1147 · Cited by 156
“Consequently, alterations in these two proteins are tightly associated with alternative lengthening of telomeres (ALT) in PanNETs (15, 16) and other tumor types (17–19).”
BackgroundDevelopmental roles of histone H3 variants and their chaperones
Filipescu, D., Szenker‐Ravi, E., & Almouzni, G. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.06.002 · Cited by 164
Venneti, S., Santi, M., Felicella, M. M., Yarilin, D. A., Phillips, J. J., Sullivan, L. M., Martínez, D., Perry, A., Lewis, P. W., Thompson, C. B., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1338-3 · Cited by 156
Alli, S., Figueiredo, C. A., Golbourn, B., Sabha, N., Wu, M. Y., Bondoc, A., Luck, A., Coluccia, D., Maslink, C., Smith, C., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.005 · Cited by 148
ROS and Brain Gliomas: An Overview of Potential and Innovative Therapeutic Strategies
Rinaldi, M., Caffo, M., Minutoli, L., Marini, H. R., Abbritti, R. V., Squadrito, F., Trichilo, V., Valenti, A., Barresi, V., Altavilla, D., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060984 · Cited by 167
“As a matter of fact, primary and secondary GBMs arise from distinct genetic pathways [18].”
BackgroundInfluentialMolecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy
Gajjar, A. J., Pfister, S. M., Taylor, M. D., & Gilbertson, R. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0833 · Cited by 158
“Themost intriguing finding, so far, has been highly recurrent hotspot mutations affecting two distinct residues (K27 and G34) of the noncanonical histone geneH3F3A, as well as the canonical histone genes HIST1H3B and HIST1H3C (3, 41, 42).”
BackgroundSelf-citationTargeting histone modifications — epigenetics in cancer
Waldmann, T., & Schneider, R. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.01.001 · Cited by 151
García-Expósito, L., Bournique, E., Bergoglio, V., Bose, A., González, J. B., Zhang, S., Roncaioli, J. L., Lee, M., Wallace, C. T., Watkins, S. C., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.048 · Cited by 158
“3-ATRX-DAXX chromatin assembly complex that have been cataloged in virtually every ALT-positive tumor (Heaphy et al., 2011; Schwartzentruber et al., 2012).”
Grill, J., Massimino, M., Bouffet, É., Azizi, A. A., McCowage, G. B., Cañete, A., Saran, F. H., Deley, M. L., Varlet, P., Morgan, P. S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0611 · Cited by 153
The genetic landscape of anaplastic pleomorphic xanthoastrocytoma
Phillips, J. J., Gong, H. Z., Chen, K. Y., Joseph, N. M., Ziffle, J. V., Bastian, B. C., Grenert, J. P., Kline, C., Mueller, S., Banerjee, A., et al. (2018) · Brain Pathology · doi:10.1111/bpa.12639 · Cited by 157
“Advances in molecular characterization of central nervous system neoplasms seek to improve tumor classification and therapeutic outcome (11,16,36,37,39,43).”
BackgroundJang, Y., Broun, A., Wang, C., Park, Y.-K., Zhuang, L., Lee, J.-E., Froimchuk, E., Liu, C., & Ge, K. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky982 · Cited by 149
“3 lysine-36-to-methionine (K36M) mutation in chon-droblastoma (26,27).”
H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2
Jain, S. U., Rashoff, A. Q., Krabbenhoft, S. D., Hoelper, D., Do, T. J., Gibson, T. J., Lundgren, S. M., Bondra, E. R., Deshmukh, S., Harutyunyan, A. S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.028 · Cited by 159
Self-citationJessa, S., Mohammadnia, A., Harutyunyan, A. S., Hulswit, M., Varadharajan, S., Lakkis, H., Kabir, N., Bashardanesh, Z., Hébert, S., Faury, D., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01205-w · Cited by 163
Self-citationAtak, Z. K., Gianfelici, V., Hulselmans, G. J., Keersmaecker, K. D., Devasia, A. G., Geerdens, E., Mentens, N., Chiaretti, S., Durinck, K., Uyttebroeck, A., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003997 · Cited by 161
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
Carter, D. R., Murray, J. E., Cheung, B. B., Gamble, L. D., Koach, J., Tsang, J., Sutton, S. K., Kalla, H., Syed, S., Gifford, A. J., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1803 · Cited by 150
“3 chaperone ATRX in neuroblastoma (14) and pediatric glioma (28).”
BackgroundThe chromatin remodelling factor ATRX suppresses R‐loops in transcribed telomeric repeats
Nguyen, D. T. T., Voon, H. P. J., Xella, B., Scott, C., Clynes, D., Babbs, C., Ayyub, H., Kerry, J., Sharpe, J. A., Sloane‐Stanley, J., et al. (2017) · EMBO Reports · doi:10.15252/embr.201643078 · Cited by 149
Benítez, J. A., Ma, J., D’Antonio, M., Boyer, A. D., Camargo, M. F., Zanca, C., Kelly, S., Khodadadi‐Jamayran, A., Jameson, N. M., Andersen, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15223 · Cited by 160
DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas
Kaina, B., & Christmann, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.007 · Cited by 150
Interplay between chromatin marks in development and disease
Janssen, S. M., & Lorincz, M. C. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00416-x · Cited by 155
PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease
Kadoch, C., Copeland, R. A., & Keilhack, H. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01191 · Cited by 140
Toledo, R. A., Qin, Y., Cheng, Z.-M., Gao, Q., Iwata, S., Silva, G. M., Prasad, M. L., Ocal, I. T., Rao, S. N., Aronin, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1841 · Cited by 153
“This differs from H3F3A mutations in bone and brain cancers, which have been detected exclusively at the somatic level (18, 20, 21).”
BackgroundTP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG)
Werbrouck, C., Evangelista, C. C. S., Lobón-Iglesias, M.-J., Barret, E., Teuff, G. L., Merlevede, J., Brusini, R., Kergrohen, T., Mondini, M., Bolle, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0126 · Cited by 158
Diverse Epigenetic Mechanisms of Human Disease
Brookes, E., & Shi, Y. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092518 · Cited by 142
The developmental origin of brain tumours: a cellular and molecular framework
Azzarelli, R., Simons, B. D., & Philpott, A. (2018) · Development · doi:10.1242/dev.162693 · Cited by 135
“3) is cell-cycle independent and is incorporated into genic euchromatin regions or pericentromeric and telomeric regions by different associated proteins: ATRX and DAXX.”
BackgroundInfluentialTelomere Maintenance Mechanisms in Cancer
Gaspar, T. B., Sá, A., Lopes, J. M., Sobrinho-Simões, M. A., Soares, P., & Vinagre, J. (2018) · Genes · doi:10.3390/genes9050241 · Cited by 158
“Such findings point towards a central role of ATRX in ALT in CNS tumours [337].”
BackgroundInfluential
Metadata
- Authors
- Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., Hovestadt, V., Albrecht, S., Kool, M., Nantel, A., Konermann, C., Lindroth, A., Jäger, N., Rausch, T., Ryzhova, M., Korbel, J. O., Hielscher, T., Hauser, P., Garami, M., Klekner, A., Bognar, L., Ebinger, M., Schuhmann, M. U., Scheurlen, W., Pekrun, A., Frühwald, M. C., Roggendorf, W., Kramm, C., Dürken, M., Atkinson, J., Lepage, P., Montpetit, A., Zakrzewska, M., Zakrzewski, K., Liberski, P. P., Dong, Z., Siegel, P., Kulozik, A. E., Zapatka, M., Guha, A., Malkin, D., Felsberg, J., Reifenberger, G., von Deimling, A., Ichimura, K., Collins, V. P., Witt, H., Milde, T., Witt, O., Zhang, C., Castelo-Branco, P., Lichter, P., Faury, D., Tabori, U., Plass, C., Majewski, J., Pfister, S. M., & Jabado, N.
- Affiliations
- McGill University and Génome Québec Innovation Centre (CA)
- German Cancer Research Center (DE)
- McGill University (CA)
- Montreal Children's Hospital (CA)
- European Molecular Biology Laboratory (DE)
- Burdenko Neurosurgery Institute (RU)
- University Children's Hospital Tübingen (DE)
- Universitätsklinikum Tübingen (DE)
- Cnopf´sche Kinderklinik (DE)
- Prof. Hess Kinderklinik (DE)
- University Hospital Augsburg (DE)
- University of Würzburg (DE)
- University Hospital in Halle (DE)
- Medical University of Lodz (PL)
- University Hospital Heidelberg (DE)
- University of Toronto (CA)
- Heinrich Heine University Düsseldorf (DE)
- University of Cambridge (GB)
- McGill University Health Centre (CA)
- Corresponding author
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- ORCID
- Schwartzentruber, Jeremy
- Korshunov, Andrey
- Jones, David T. W.
- Pfaff, Elke
- Sturm, Dominik
- Hovestadt, Volker
- Albrecht, Steffen
- Kool, Marcel
- Lindroth, Anders
- Jäger, Natalie
- Rausch, Tobias
- Ryzhova, Marina
- Korbel, Jan O.
- Hielscher, Thomas
- Ebinger, Martin
- Schuhmann, Martin U.
- Frühwald, Michael C.
- Dürken, Matthias
- Atkinson, Jeffrey
- Lepage, Pierre
- Zakrzewska, Magdalena
- Liberski, Pawel P.
- Siegel, Peter
- Kulozik, Andreas E.
- Zapatka, Marc
- Guha, Abhijit
- Malkin, David
- Felsberg, Jörg
- Reifenberger, Guido
- Ichimura, Koichi
- Collins, V. Peter
- Witt, Hendrik
- Milde, Till
- Witt, Olaf
- Zhang, Cindy
- Lichter, Peter
- Faury, Damien
- Tabori, Uri
- Plass, Christoph
- Majewski, Jacek
- Pfister, Stefan M.
- Jabado, Nada
- Venue
- Nature
- Published
- 2012-01-29
- Volume
- 482
- Issue
- 7384
- Pages
- 226-231
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2158233796
- Cited by
- 2,631
- References
- 35
- Citations by year
- 2026: 109 · 2025: 138 · 2024: 188 · 2023: 189 · 2022: 200 · 2021: 226 · 2020: 238 · 2019: 188 · 2018: 166 · 2017: 200 · 2016: 174 · 2015: 165 · 2014: 189 · 2013: 166 · 2012: 90
- FWCI
- 92.99
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-03-28)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- NPARC (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Funders
- Cancer Research Institute
- Genome Canada
- Brain Tumour Charity (10/106)
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- H3F3A mutation, histone H3.3, ATRX mutation, chromatin remodeling, somatic mutations, TP53 mutation, H3K27M mutation, histone modifications, histone deacetylase inhibitors
- MeSH terms
- X-linked Nuclear Protein, Base Sequence, Child, Chromatin, DNA Mutational Analysis, DNA Helicases, Glioblastoma, Histones, Humans, Molecular Sequence Data, Mutation, Nuclear Proteins, Tumor Suppressor Protein p53, Telomere, Molecular Chaperones, Gene Expression Profiling, Chromatin Assembly and Disassembly, Adaptor Proteins, Signal Transducing, Co-Repressor Proteins, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.